BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 22691924)

  • 21. The diagnosis and management of NK/T-cell lymphomas.
    Tse E; Kwong YL
    J Hematol Oncol; 2017 Apr; 10(1):85. PubMed ID: 28410601
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nasal-type extranodal natural killer/T-cell lymphoma presenting with extensive leg ulcers.
    Chia HY; Tey HL; Tan KB; Chong WS
    Clin Exp Dermatol; 2009 Dec; 34(8):e693-5. PubMed ID: 20055838
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Extranodal natural killer/T cell lymphoma: we should and we can do more.
    Ying Z; Zhu J
    Chin Clin Oncol; 2015 Mar; 4(1):12. PubMed ID: 25841719
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [A multi-center retrospective study of L-asparaginase-based regimens as first-line treatment in newly diagnosed extranodal NK/T-cell lymphoma].
    Yuan F; Wei X; Yin Q; Li Y; Mi R; Ai H; Yang H; Li H; Ge S; Liu Y; Song Y
    Zhonghua Xue Ye Xue Za Zhi; 2014 Jul; 35(7):614-8. PubMed ID: 25052604
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Extranodal NK/T-cell lymphoma].
    Suzuki R
    Nihon Rinsho; 2014 Mar; 72(3):524-30. PubMed ID: 24724414
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment of advanced extranodal NK/T cell lymphoma, nasal-type and aggressive NK-cell leukemia.
    Suzuki R
    Int J Hematol; 2010 Dec; 92(5):697-701. PubMed ID: 21116747
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Advances of treatment for extranodal NK/T-cell lymphoma --- review].
    Zhang SS; Wei M; Yu L
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Aug; 19(4):1075-8. PubMed ID: 21867647
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CD56-negative extranodal nasal type NK/T-cell lymphoma.
    Miles RR; Afify Z; Yaish H; Perkins SL
    Pediatr Blood Cancer; 2010 Jul; 55(1):186-9. PubMed ID: 20486184
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Activated oncogenic pathways and therapeutic targets in extranodal nasal-type NK/T cell lymphoma revealed by gene expression profiling.
    Ng SB; Selvarajan V; Huang G; Zhou J; Feldman AL; Law M; Kwong YL; Shimizu N; Kagami Y; Aozasa K; Salto-Tellez M; Chng WJ
    J Pathol; 2011 Mar; 223(4):496-510. PubMed ID: 21294123
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A unique case of adolescent CD56-negative extranodal NK/T-cell lymphoma, nasal type.
    Chang BH; Stork L; Fan G
    Pediatr Dev Pathol; 2008; 11(1):50-4. PubMed ID: 18237230
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical study of l-asparaginase in the treatment of extranodal NK/T-cell lymphoma, nasal type.
    Yong W
    Hematol Oncol; 2016 Jun; 34(2):61-8. PubMed ID: 25899032
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Prognosis and treatment strategies of primary B-cell and NK/T-cell nasopharyngeal non-Hodgkin's lymphoma at early stage].
    Zou GR; Zhang YJ; Xie FY; Zheng W; Li HX; Xia YF; Lin TY; Lu TX
    Ai Zheng; 2006 Dec; 25(12):1543-9. PubMed ID: 17166383
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Classification of cell lineage and anatomical site, and prognosis of extranodal T-cell lymphoma -- natural killer cell, cytotoxic T lymphocyte, and non-NK/CTL types.
    Ohshima K; Liu Q; Koga T; Suzumiya J; Kikuchi M
    Virchows Arch; 2002 Apr; 440(4):425-35. PubMed ID: 11956825
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Differential clinical significance of pre-, interim-, and post-treatment plasma Epstein-Barr virus DNA load in NK/T-cell lymphoma treated with P-GEMOX protocol.
    Wang XX; Li PF; Bai B; Gao Y; Rong QX; Cai QQ; Lin SX; Zhang YJ; Li ZM; Jiang WQ; Huang HQ
    Leuk Lymphoma; 2019 Aug; 60(8):1917-1925. PubMed ID: 30646796
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Successful treatment with high-dose methotrexate/cytarabine regimen in a patient in SMILE regimen-resistant extranodal natural killer/T-cell lymphoma].
    Saburi M; Itani K; Nagamatsu K; Miyazaki Y; Otsuka E; Urabe S; Saburi Y
    Rinsho Ketsueki; 2014 Jan; 55(1):120-4. PubMed ID: 24492044
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Primary colonic extranasal NK/T-cell lymphoma: about a case].
    Fares S; Lamchahab M; Aniba M; Lembarki G; Mousalli N; Regragui M; Karkouri M; Quessar A
    Pan Afr Med J; 2017; 26():112. PubMed ID: 28533835
    [TBL] [Abstract][Full Text] [Related]  

  • 38. L-asparaginase-based regimens followed by allogeneic hematopoietic stem cell transplantation improve outcomes in aggressive natural killer cell leukemia.
    Jung KS; Cho SH; Kim SJ; Ko YH; Kang ES; Kim WS
    J Hematol Oncol; 2016 Apr; 9():41. PubMed ID: 27091029
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Non-Hodgkin's lymphoma of the paranasal sinuses: clinical and pathological features, and response to combined-modality therapy.
    Hausdorff J; Davis E; Long G; Hoppe R; van der Pas M; Lassman C; Kamel O; Jacobs C
    Cancer J Sci Am; 1997; 3(5):303-11. PubMed ID: 9327155
    [TBL] [Abstract][Full Text] [Related]  

  • 40. NF-kappaB activation through the alternative pathway correlates with chemoresistance and poor survival in extranodal NK/T-cell lymphoma, nasal type.
    Liu X; Wang B; Ma X; Guo Y
    Jpn J Clin Oncol; 2009 Jul; 39(7):418-24. PubMed ID: 19395464
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.